InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,313.27
(
0.10%
)
US TECH 100
18,196.60
(
0.00%
)
Dow Jones
39,835.76
(
0.07%
)
Brent Oil
82.66
(
-1.05%
)
Bitcoin
69,651.68
(
-2.52%
)
Post# of 251872
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Mufaso

Send PM Follow Ignore
Followers 27
Posts 452
Boards Moderated 0
Alias Born 01/08/2008

Mufaso

Member Level

Re: Mufaso post# 251095

Tuesday, 03/26/2024 7:16:14 AM

Tuesday, March 26, 2024 7:16:14 AM

Post# of 251872
Viking Therapeutics Announces Results from Phase 1 Clinical Trial of Oral Tablet Formulation of Dual GLP-1/GIP Receptor Agonist VK2735

https://ir.vikingtherapeutics.com/2024-03-26-Viking-Therapeutics-Announces-Results-from-Phase-1-Clinical-Trial-of-Oral-Tablet-Formulation-of-Dual-GLP-1-GIP-Receptor-Agonist-VK2735

  • Up to 3.3% Placebo-Adjusted Mean Weight Loss (5.3% from Baseline) Observed After 28 Days

  • VK2735 Shown to be Safe and Well-Tolerated in 28-Day Study with Low Rates of GI-Related Adverse Events

  • Phase 2 Trial in Obesity Planned for 2H24

"People are best convinced by reasons they discover themselves"

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up